NEW YORK – Multiomics company Pleno said Thursday that it has closed a $25 million Series B funding round.
The company said it plans to use the funds to scale the development and commercialization of its RAPTOR multiomics platform.
The round included investment from Deerfield Management, Foresite Capital, and Medical Excellence Capital.
Pleno also announced that it has appointed Vik Vaz as its new CEO and member of its board of directors, effective immediately. Vaz was previously head of strategy and market intelligence and a leader of the companion diagnostics business at Illumina. Prior to that, he worked as a partner at the Boston Consulting Group and McKinsey and Company. He replaces former CEO and Founder Pieter van Rooyen.
Pleno's RAPTOR platform allows the targeted measurement of large numbers of nucleic acids and is intended as a more streamlined, less expensive, and higher-throughput alternative to next-generation sequencing in applications requiring analysis of large numbers of known nucleic acid targets. Based on so-called Hypercoding technology, the platform will be capable of detecting up to 10,000 nucleic acid targets per sample and processing up to 10,000 samples per day, Pleno has said.
The Series B round follows a $40 million Series A round the company closed in 2022.